New insights into cancer immunoediting and its three component phases—elimination, equilibrium and escape

Grivennikov, 2010, Immunity, inflammation, and cancer, Cell, 140, 883, 10.1016/j.cell.2010.01.025

Shankaran, 2001, IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity, Nature, 410, 1107, 10.1038/35074122

Dunn, 2006, Interferons, immunity and cancer immunoediting, Nat Rev Immunol, 6, 836, 10.1038/nri1961

Burnet, 1957, Cancer; a biological approach. I. The processes of control, Br Med J, 1, 779, 10.1136/bmj.1.5022.779

Schreiber, 2011, Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion, Science, 331, 1565, 10.1126/science.1203486

Dunn, 2004, The immunobiology of cancer immunosurveillance and immunoediting, Immunity, 21, 137, 10.1016/j.immuni.2004.07.017

Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013

Matsushita, 2012, Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting, Nature, 482, 400, 10.1038/nature10755

DuPage, 2012, Expression of tumour-specific antigens underlies cancer immunoediting, Nature, 482, 405, 10.1038/nature10803

DuPage, 2011, Endogenous T cell responses to antigens expressed in lung adenocarcinomas delay malignant tumor progression, Cancer Cell, 19, 72, 10.1016/j.ccr.2010.11.011

Castle, 2012, Exploiting the mutanome for tumor vaccination, Cancer Res, 72, 1081, 10.1158/0008-5472.CAN-11-3722

Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat Med, 19, 747, 10.1038/nm.3161

van Rooij, 2013, Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma, J Clin Oncol, 10, e439, 10.1200/JCO.2012.47.7521

von Boehmer, 2013, NY-ESO-1-specific immunological pressure and escape in a patient with metastatic melanoma, Cancer Immunol, 13, 12

Nicholaou, 2011, Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX, Cancer Immunol Immunotherapy, 60, 1625, 10.1007/s00262-011-1041-3

O'Sullivan, 2012, Cancer immunoediting by the innate immune system in the absence of adaptive immunity, J Exp Med, 209, 1869, 10.1084/jem.20112738

Vesely, 2011, Natural innate and adaptive immunity to cancer, Annu Rev Immunol, 29, 235, 10.1146/annurev-immunol-031210-101324

Diamond, 2011, Type I interferon is selectively required by dendritic cells for immune rejection of tumors, J Exp Med, 208, 1989, 10.1084/jem.20101158

Fuertes, 2011, Host type I IFN signals are required for antitumor CD8+ T cell responses through CD8{alpha}+ dendritic cells, J Exp Med, 208, 2005, 10.1084/jem.20101159

Senovilla, 2012, An immunosurveillance mechanism controls cancer cell ploidy, Science, 337, 1678, 10.1126/science.1224922

Croxford, 2013, ATM-dependent spontaneous regression of early Emu-myc-induced murine B-cell leukemia depends on natural killer and T cells, Blood, 121, 2512, 10.1182/blood-2012-08-449025

Iannello, 2013, p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells, J Exp Med, 210, 2057, 10.1084/jem.20130783

Gasser, 2005, The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor, Nature, 436, 1186, 10.1038/nature03884

Liu, 2012, Ras activation induces expression of Raet1 family NK receptor ligands, J Immunol, 189, 1826, 10.4049/jimmunol.1200965

Kang, 2011, Senescence surveillance of pre-malignant hepatocytes limits liver cancer development, Nature, 479, 547, 10.1038/nature10599

Biroccio, 2013, TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells, Nat Cell Biol, 15, 818, 10.1038/ncb2774

Willingham, 2012, The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors, Proc Natl Acad Sci U S A, 109, 6662, 10.1073/pnas.1121623109

Weiskopf, 2013, Engineered SIRPalpha variants as immunotherapeutic adjuvants to anticancer antibodies, Science, 341, 88, 10.1126/science.1238856

Koebel, 2007, Adaptive immunity maintains occult cancer in an equilibrium state, Nature, 450, 903, 10.1038/nature06309

Teng, 2012, Opposing roles for IL-23 and IL-12 in maintaining occult cancer in an equilibrium state, Cancer Res, 72, 3987, 10.1158/0008-5472.CAN-12-1337

Wu, 2013, Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma, Cancer Lett, 340, 124, 10.1016/j.canlet.2013.07.038

Muller-Hermelink, 2008, TNFR1 signaling and IFN-gamma signaling determine whether T cells induce tumor dormancy or promote multistage carcinogenesis, Cancer Cell, 13, 507, 10.1016/j.ccr.2008.04.001

Braumuller, 2013, T-helper-1-cell cytokines drive cancer into senescence, Nature, 494, 361, 10.1038/nature11824

Mellman, 2011, Cancer immunotherapy comes of age, Nature, 480, 480, 10.1038/nature10673

Gajewski, 2011, Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment, Curr Opin Immunol, 23, 286, 10.1016/j.coi.2010.11.013

Mantovani, 2010, Macrophages, innate immunity and cancer: balance, tolerance, and diversity, Curr Opin Immunol, 22, 231, 10.1016/j.coi.2010.01.009

Beavis, 2012, CD73: a potent suppressor of antitumor immune responses, Trends Immunol, 33, 231, 10.1016/j.it.2012.02.009

Beavis, 2013, Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors, Proc Natl Acad Sci U S A, 110, 14711, 10.1073/pnas.1308209110

Wang, 2011, VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses, J Exp Med, 208, 577, 10.1084/jem.20100619

Ceeraz, 2013, B7 family checkpoint regulators in immune regulation and disease, Trends Immunol, 34, 556, 10.1016/j.it.2013.07.003

Hobo, 2012, B and T lymphocyte attenuator mediates inhibition of tumor-reactive CD8+ T cells in patients after allogeneic stem cell transplantation, J Immunol, 189, 39, 10.4049/jimmunol.1102807

Fourcade, 2012, CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1, Cancer Res, 72, 887, 10.1158/0008-5472.CAN-11-2637

Marabelle, 2013, Depleting tumor-specific Tregs at a single site eradicates disseminated tumors, J Clin Investig, 123, 2447, 10.1172/JCI64859

Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat Rev Cancer, 12, 252, 10.1038/nrc3239

Vanneman, 2012, Combining immunotherapy and targeted therapies in cancer treatment, Nat Rev Cancer, 12, 237, 10.1038/nrc3237

Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466

Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N Engl J Med, 366, 2455, 10.1056/NEJMoa1200694

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, 366, 2443, 10.1056/NEJMoa1200690

Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369

Dranoff, 2013, Immunotherapy at large: balancing tumor immunity and inflammatory pathology, Nat Med, 19, 1100, 10.1038/nm.3335

Angell, 2013, From the immune contexture to the Immunoscore: the role of prognostic and predictive immune markers in cancer, Curr Opin Immunol, 25, 261, 10.1016/j.coi.2013.03.004

Galon, 2013, The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures, Immunity, 39, 11, 10.1016/j.immuni.2013.07.008

Mlecnik, 2010, Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer, Gastroenterology, 138, 1429, 10.1053/j.gastro.2009.10.057

Gajewski, 2013, Innate and adaptive immune cells in the tumor microenvironment, Nat Immunol, 14, 1014, 10.1038/ni.2703

Balachandran, 2011, Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido, Nat Med, 17, 1094, 10.1038/nm.2438

Delahaye, 2011, Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors, Nat Med, 17, 700, 10.1038/nm.2366

Weiss, 2011, Molecular insights on the peripheral and intratumoral effects of systemic high-dose rIL-2 (aldesleukin) administration for the treatment of metastatic melanoma, Clin Cancer Res, 17, 7440, 10.1158/1078-0432.CCR-11-1650

Ulloa-Montoya, 2013, Predictive gene signature in MAGE-A3 antigen-specific cancer immunotherapy, J Clinl Oncol, 31, 2388, 10.1200/JCO.2012.44.3762

Ji, 2012, An immune-active tumor microenvironment favors clinical response to ipilimumab, Cancer Immunol Immunotherapy, 61, 1019, 10.1007/s00262-011-1172-6

Halama, 2011, Localization and density of immune cells in the invasive margin of human colorectal cancer liver metastases are prognostic for response to chemotherapy, Cancer Res, 71, 5670, 10.1158/0008-5472.CAN-11-0268

Ignatiadis, 2012, Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis, J Clin Oncol, 30, 1996, 10.1200/JCO.2011.39.5624

Denkert, 2010, Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer, J Clin Oncol, 28, 105, 10.1200/JCO.2009.23.7370

Tosolini, 2011, Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, th2, treg, th17) in patients with colorectal cancer, Cancer Res, 71, 1263, 10.1158/0008-5472.CAN-10-2907

Grivennikov, 2012, Adenoma-linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth, Nature, 491, 254, 10.1038/nature11465

Schwabe, 2013, The microbiome and cancer, Nat Rev Cancer, 13, 800, 10.1038/nrc3610